Intest Res > Volume 22(1); 2024 > Article |
|
Funding Source
This work was supported by the National Research Foundation (NRF) grant funded by the Korea government (MSIT), awarded to Lee SB (No. 2020R1G1A1006795).
Author Contributions
Conceptualization: Lee SB, Park SH (5th). Data curation: Lee SB, Park SH (5th). Formal analysis: Lee SB, Park SH (5th). Funding acquisition: Lee SB. Investigation: Kim HK, Park SH (3rd), Lim JH. Methodology: Kim HK, Park SH (3rd), Lim JH. Supervision: Park SH (5th). Writing - original draft: Lee SB, Kim HK. Writing - review & editing: Park SH (5th). Approval of final manuscript: all authors.
Characteristic | Total patients (n = 48) |
---|---|
Age at diagnosis (yr), median (IQR) | 29 (22-45) |
Sex, No. (%) | |
Male | 29 (60.4) |
Female | 19 (39.6) |
Diagnosis, No. (%) | |
Ulcerative colitis | 20 (41.7) |
E1/E2/E3a | 0/5/15 |
Crohn’s disease | 28 (58.3) |
L1/L2/L3a | 5/0/23 |
Concomitant medication, No. (%) | |
5-Aminosalicyclates | 12 (25.0) |
Immunomodulator (AZA/6-MP) | 15 (31.3) |
Anti-TNF-α antibody | 7 (14.6) |
Vedolizumab | 9 (18.8) |
Ustekinumab | 4 (8.3) |
Tofacitinib | 1 (2.1) |
Laboratory data, median (IQR) | |
Ischemia-modified albumin (U/mL) | 72.3 (68.7-77.7) |
Fecal calprotectin (mg/kg) | 165.5 (87.7-332.1) |
ESR (mm/hr) | 11 (5-35) |
Serum CRP (mg/dL) | 0.18 (0.07-0.59) |
Serum albumin (g/dL) | 4.4 (4.1-4.6) |
a Subgroups were divided according to the Montreal classification [19].
Characteristic |
Endoscopic mucosal healing |
P-value | ||
---|---|---|---|---|
Yes (n=23) | No (n=25) | |||
Age at diagnosis (yr), median (IQR)a | 30 (25-45) | 28 (20-46) | 0.861 | |
Sex, No. (%) | 0.951 | |||
Male | 14 (60.9) | 15 (60.0) | ||
Female | 9 (39.1) | 10 (40.0) | ||
Diagnosis, No. (%) | 0.157 | |||
Ulcerative colitis | 12 (52.2) | 8 (32.0) | ||
Crohn’s disease | 11 (47.8) | 17 (68.0) | ||
Concomitant medications, No. (%) | 0.754 | |||
5-Aminosalicyclates | 6 (26.1) | 6 (24.0) | ||
Immunomodulator (AZA/6-MP) | 6 (26.1) | 9 (36.0) | ||
Biologics and tofacitinib | 11 (47.8) | 10 (40.0) | ||
Biochemical markers, median (IQR)a | ||||
Ischemia-modified albumin (U/mL) | 69.3 (65.2-72.7) | 75.5 (70.9-78.2) | < 0.001 | |
Fecal calprotectin (mg/kg) | 82.4 (24.8-146.3) | 292.6 (165.5-521.4) | < 0.001 | |
ESR (mm/hr) | 10 (4-30) | 12 (6-35) | 0.516 | |
Serum CRP (mg/dL) | 0.12 (0.04-0.43) | 0.33 (0.10-0.89) | 0.040 | |
Serum albumin (g/dL) | 4.4 (4.1-4.8) | 4.4 (4.0-4.5) | 0.225 |